The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...

AbbVie’s Elahere (mirvetuximab soravtansine-gynx) has demonstrated consistent survival benefits in a subset of ovarian cancer ...

The phase 3 REDEFINE 2 trial has been evaluating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide ...

Not many people would pay for a ticket to a concert where their seat was positioned behind a pillar and directly below the ...

PMLiVE’s Top Pharma List is live!; Omnichannel – breaking down the barriers; Rare diseases – improving patient access ...

AstraZeneca (AZ) has announced that it will be expanding its cell therapy capabilities by acquiring EsoBiotec for up to $1bn. The deal will give AZ access to EsoBiotec’s Engineered NanoBody Lentiviral ...

The National Institute for Health and Care Excellence (NICE) has recommended Pharming’s Joenja (leniolisib) to treat patients with the ultra-rare immune disease, activated phosphoinositide 3-kinase ...

Boehringer Ingelheim (BI) and Salipro Biotech have entered into a partnership aimed at accelerating the development of ...

Prime Minister Sir Keir Starmer announced the abolition of NHS England to "cut bureaucracy" and bring management of the ...

Cheers to 15 years of patient recruitment and retention innovation and impact at Innovative Trials! 🎉 From 2010 to 2025, we’ve been on an incredible journey of growth, impact, and innovation. We ...

Bristol Myers Squibb (BMS) has received approval from the European Commission (EC) for its CD19-directed CAR T cell therapy ...

Roche has announced the launch of a new cardiovascular, renal and metabolism (CVRM) hub at Harvard’s Enterprise Research ...